Xilio Therapeutics (NASDAQ:XLO) Releases Earnings Results

Posted by Brenda Bartman on May 14th, 2026

Xilio Therapeutics (NASDAQ:XLO – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.08, FiscalAI reports. The company had revenue of $12.65 million for the quarter, compared to analysts’ expectations of $8.52 million. Xilio Therapeutics had a negative return on equity of 354.12% and a negative net margin of 58.52%.

Xilio Therapeutics Stock Up 0.4%

Shares of Xilio Therapeutics stock opened at $7.76 on Thursday. The firm has a market cap of $46.40 million, a P/E ratio of -2.18 and a beta of -0.16. Xilio Therapeutics has a fifty-two week low of $6.47 and a fifty-two week high of $16.10. The business has a 50-day moving average price of $8.06 and a 200 day moving average price of $8.99.

Analyst Ratings Changes

A number of research analysts have commented on XLO shares. Wall Street Zen upgraded Xilio Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Weiss Ratings upgraded Xilio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $28.00.

Read Our Latest Research Report on Xilio Therapeutics

Institutional Trading of Xilio Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp grew its holdings in shares of Xilio Therapeutics by 13.7% during the fourth quarter. State Street Corp now owns 186,390 shares of the company’s stock valued at $119,000 after purchasing an additional 22,500 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Xilio Therapeutics during the fourth quarter valued at approximately $27,000. Squarepoint Ops LLC grew its holdings in shares of Xilio Therapeutics by 39.6% during the third quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock valued at $277,000 after purchasing an additional 93,338 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Xilio Therapeutics by 68.3% during the fourth quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock valued at $220,000 after purchasing an additional 139,716 shares during the last quarter. Finally, Velan Capital Investment Management LP bought a new position in shares of Xilio Therapeutics during the fourth quarter valued at approximately $109,000. 54.29% of the stock is owned by institutional investors.

Xilio Therapeutics Company Profile

(Get Free Report)

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.